FDA approves Onfi™ (clobazam) for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome
24 October 2011 | By H. Lundbeck A/S
The FDA has approved Onfi™ (clobazam)...
List view / Grid view
News
Gilead and GlobeImmune announce license and collaboration agreement to develop therapeutic vaccine products
24 October 2011 | By Gilead Sciences Inc
Gilead & GlobeImmune enter into an exclusive worldwide license & collaboration agreement...
Abbott’s genetic test for acute myeloid leukemia prognosis cleared by FDA
24 October 2011 | By Abbott
New test based on FISH technology detects chromosomal abnormality to help predict prognosis of patients with AML...
Novartis Phase II data show AIN457 provided rapid and significant relief of symptoms in up to 81% of patients with psoriasis
24 October 2011 | By Novartis
Positive results from three Phase II trials...
Sanofi appoints David Meeker as Genzyme’s new Chief Executive Officer
24 October 2011 | By Sanofi
Sanofi announced the appointment of David Meeker as Chief Executive Officer of Genzyme, effective November 1, 2011...
Merck announces presentation of Phase III investigational studies evaluating DULERA® (mometasone furoate and formoterol fumarate dihydrate) inhalation aerosol in COPD
24 October 2011 | By Merck
Merck announced results from two 26-week investigational Phase III clinical studies...
Biogen Idec and Abbott present positive data for Daclizumab HYP from Select Phase 2b trial at ECTRIMS/ACTRIMS
22 October 2011 | By Biogen Idec
Biogen Idec and Abbott announced additional results from the SELECT Phase 2b trial...
Alemtuzumab significantly reduces relapses in multiple sclerosis vs interferon beta-1a in a Phase III study
22 October 2011 | By Sanofi
New results from the CARE-MS I trial...
Janssen data focus on tolerability and treatment simplification in HIV compounds
21 October 2011 | By Janssen Pharmaceuticals Inc.
New HIV data to be presented at EACS 2011...
Oral BG-12 (Dimethyl Fumarate) significantly reduced multiple sclerosis (MS) relapses and disability progression
21 October 2011 | By Biogen Idec
Phase 3 clinical trial demonstrated significant clinical effects...
ICON selected by the Biomarkers Consortium of the FNIH
21 October 2011 | By ICON plc
ICON has announced it has received a contract award from the Foundation for the National Institutes of Health (FNIH)...
STELARA® (Ustekinumab) is effective, well-tolerated and improves quality of life in patients with moderate to severe plaque psoriasis inadequately responsive to methotrexate[1,2]
21 October 2011 | By Johnson and Johnson
New data presented at EADV...
AstraZeneca to present new healthcare economics data demonstrating cost-effectiveness of BRILIQUE
21 October 2011 | By AstraZeneca
AstraZeneca will present key results from health economics sub-studies...
Phase II study showed ocrelizumab maintained significant reduction in disease activity for MS patients
20 October 2011 | By Roche
Phase III trials underway to investigate ocrelizumab in two forms of MS...
Abbott to separate into two leading companies
19 October 2011 | By Abbott
Abbott plans to separate into two companies, one in diversified medical products & the other in research-based pharmaceuticals...
